Document text
Principal Investigator: TOMAS KIRCHHAUSEN
Organization: WASHINGTON UNIVERSITY
Fiscal Year: 2023
Award: $752,346
Funding agency: National Institute of Allergy and Infectious Diseases
The long term goal of this study is to understand how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of coronavirus disease 2019 (COVID-19), enters cells and how to block that process through the use of therapeutics. Like other enveloped viruses, SARS-CoV-2 cell entry begins with engagement at the cell-surface and is completed on release of the viral contents following membrane fusion. During the process of cell entry, the SARS-CoV-2 spike protein (S) engages the cellular receptor, angiotensin converting enzyme (ACE2). Proteolytic activation of S is required to activate the fusion machinery which can be achieved by cell surface or endosomal proteases positing a model of cell surface and endosomal entry routes that depend on engagement of different host-cell molecules that vary among cell types. To interrogate the entry pathway of SARS-CoV-2 we developed a set of unique tools that permit application of single virion imaging approaches to track productive entry routes in an unbiased way and to help identify host factors coopted during viral entry. This imaging is facilitated by the use of a chimeric vesicular stomatitis virus (VSV) in which its glycoprotein gene (G) was replaced with the spike (S) gene of SARS-CoV-2. Inhibition of VSV-SARS-CoV-2 infection with monoclonal antibodies, soluble receptor and small molecule inhibitors correlates closely with inhibition of a clinical isolate of SARS-CoV-2, corroborating that the chimera is an effective BSL2 surrogate to study SARS-CoV-2 S-mediated entry. This permits us to genetically modify a core protein of the VSV ribonucleoprotein core to render the particles visible by fluorescent microscopy. By combining this imaging approach, with genetic, chemical and biological perturbations, we will map the entry routes of VSV-SARS-CoV-2 and then examine the effect of those perturbations on infection of cells with a clinical isolate of SARS-CoV-2. We will use this approach to determine how countermeasures currently in clinical trials including monoclonal antibodies, soluble ACE2, and two small molecule inhibitors apilimod and nafamostat block entry. Using genome-wide loss-of-function screens we will also interrogate the requirements for entry of SARS-CoV-2, under native and perturbed conditions to uncover new host proteins that are coopted during entry as potential additional targets for therapeutic intervention. Successful completion of this work will define the entry pathways that lead to productive SARS-CoV-2 infection, inform the mechanism by which multiple molecules in clinical development interfere with that process and unearth new host factors that are coopted during the entry pathway.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><Angiotensin Converting Enzyme><Angiotensin I-Converting Enzyme><Antibodies><Biochemical><Biological><CD143 Antigens><COVID-19><COVID-19 S protein><COVID-19 infection><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 virus><COVID-19 virus infection><COVID19><COVID19 S protein><COVID19 infection><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 virus><CRISPR editing screen><CRISPR screen><CRISPR-based screen><CRISPR/Cas9 screen><CV-19><CV19><Carboxycathepsin><Cathepsins><Cell Body><Cell Function><Cell Process><Cell membrane><Cell model><Cell physiology><Cell surface><Cells><Cellular Function><Cellular Physiology><Cellular Process><Cellular model><Chemicals><Chimera><Chimera organism><Clinical><Clinical Treatment Moab><Clinical Trials><CoV-2><CoV2><Complement><Complement Proteins><Core Protein><Coronaviridae><Coronavirus><Coupled><Cytoplasmic Membrane><Data><Dependence><Dipeptidyl Peptidase A><Endosomes><Epitheliasin Gene><Escape Mutant><Esteroproteases><Exhibits><Fluorescence Light Microscopy><Fluorescence Microscopy><Genes><Genetic><Genetic Screening><Glycoproteins><Goals><Heparan Sulfate><Heparitin Sulfate><Host Factor><Host Factor Protein><Human><Image><Individual><Infection><Integration Host Factors><Integrins><Integrins Extracellular Matrix><Interruption><Kininase A><Kininase II><Maps><Mediating><Membrane><Membrane Fusion><Mice><Mice Mammals><Microscopy><Modern Man><Molecular><Monoclonal Antibodies><Murine><Mus><N-Acetylneuraminic Acids><NRP1><NRP1 gene><Neuropilins><Optics><PRSS10><Pathway interactions><Peptidases><Peptide Hydrolases><Peptidyl-Dipeptidase A><Phosphoproteins><Plasma Membrane><Process><Productivity><Protease Gene><Proteases><Protein Cleavage><Proteinases><Proteins><Proteolysis><Proteolytic Enzymes><Reagent><Receptor Protein><Receptosomes><Ribonucleoproteins><Route><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CO-V2><SARS-COVID-2><SARS-CoV><SARS-CoV-1><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 entry inhibitor><SARS-CoV-2 infection><SARS-CoV-2 inhibitor><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 infection><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Serine Endopeptidases><Serine Protease><Serine Protein Hydrolases><Serine Proteinases><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 entry inhibitor><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 inhibitor><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome related corona virus 2><Sialic Acids><Subcellular Process><TMPRSS2><TMPRSS2 gene><Therapeutic><Therapeutic Intervention><Therapeutic Uses><VEGF165R><VSV><Vesicular Stomatitis Virus><Vesicular stomatitis Indiana virus><Viral><Viral Diseases><Virion><Virus><Virus Diseases><Virus Particle><Work><Wuhan coronavirus><biologic><block SARS-CoV-2><block SARS-CoV-2 entry><block severe acute respiratory syndrome coronavirus 2><block severe acute respiratory syndrome coronavirus 2 entry><cell imaging><cell type><cellular imaging><chimeras><clinical development><clustered regularly interspaced short palindromic repeats screen><corona virus><corona virus disease 2019><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 infection><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 virus><coronavirus disease-19><coronavirus disease-19 virus><coronavirus infectious disease-19><experiment><experimental research><experimental study><experiments><functional outcomes><genome scale><genome-wide><genomewide><hCoV19><imaging><imaging approach><imaging based approach><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><inhibit SARS-CoV-2><inhibit SARS-CoV-2 entry><inhibit severe acute respiratory syndrome coronavirus 2><inhibit severe acute respiratory syndrome coronavirus 2 entry><intervention therapy><loss of function><mAbs><membrane structure><monoclonal Abs><mutant><nCoV2><optical><particle><pathway><plasmalemma><receptor><receptor binding><receptor bound><severe acute respiratory syndrome-CoV><small molecule><small molecule inhibitor><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><tissue tropism><tool><trafficking><uptake><viral infection><virus infection><virus-induced disease>